Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

April 30, 2020

NASDAQ US Health Care Biotechnology earnings 42 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thanks a lot, operator, and hello to everybody this afternoon. We appreciate you being with us for Corvus Pharmaceuticals' First Quarter 2020 Business Update and Financial Results conference call. Here to talk through the results and business highlights for 2020's first quarter are Richard Miller, our Chief Executive Officer, Leiv Lea, our Chief Financial Officer, and Mehrdad Mobasher, our Chief Medical Officer. The executive team will kick things off with prepared remarks, and after that we'll take questions. I want to remind all of you that today's management comments, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could make actual results differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus's quarterly report on Form 10-Q, filed with the SEC today, plus other filings the company makes with the SEC from time to time. Except where the law requires it, the company assumes no obligation to publicly update or revise any forward-looking statements. With that said, I'll hand the call over to Leiv Lea. Leiv?

Leiv Lea

executive
#2

Thanks, Zack. I'll start by giving a brief review of the financial results from our first quarter of 2020, and after that I'll pass things to Richard for an update on the business. As of March 31st, 2020, Corvus held cash equivalents along with marketable securities amounting to $68.7 million, versus $78 million on December 31st, 2019. R&D expenses during the first quarter of 2020 came to $10.2 million, against $9.4 million in the comparable period of 2019. Pardon me. That $0.8 million rise largely reflected a $1.3 million bump in costs tied to the CPI-006 clinical trial, partly offset by a $0.9 million decrease in manufacturing costs for CPI-818. Our net loss for the first quarter of 2020 reached $12.9 million, versus a net loss of $11.6 million in the comparable period of 2019. Stock compensation expense overall in the first quarter of 2020 was $1.8 million, against $2 million in the comparable period of 2019. I want to point out that we keep managing our costs prudently, particularly given the COVID-19 pandemic. Enrollment across our trials for all three programs has been robust, at times running ahead of plan. That lets us concentrate on monitoring and follow-up, and leaves us less reliant on enrolling new patients, which COVID-19 has impacted. As Richard will explain, we expect the net effect of this slowdown to be minimal when it comes to our capacity to keep moving our lead program, ciforadenant, forward. In view of the COVID-19 situation and our progress with the ciforadenant program, which has more than 300 patients enrolled so far, we plan to sharpen our focus on our lead asset as we build out our registration strategy and move toward a planned pivotal trial. Consequently, we now anticipate net cash used in operating activities for the full year 2020 to land between $29 million and $31 million. That's roughly a $10 million decrease from what we previously expected, which was net cash used in operating activities of between $39 million and $42 million. I'll now hand the call over to Richard.

Richard Miller

executive
#3

Thank you, Leiv, and hello everyone on this call this afternoon. We're glad you could join us as we go over what's new in our business for Q1 2020. Throughout the first quarter, we continued advancing our pipeline of oncology therapies designed to hit precise targets, enrolling patients into ongoing trials and presenting fresh data at medical conferences regarding ciforadenant, the adenosine gene signature, and CPI-818. At the same time, COVID-19 turned into a global pandemic, upending daily routines for most individuals, medical professionals, patients, and companies throughout the United States. At Corvus, the wellbeing and safety of our staff, our clinical collaborators, and the patients those collaborators care for is our top priority. We acted quickly to get in touch and work alongside the sites running our trials, adjusting our study plans so that people already enrolled could be taken care of despite possible interruptions. The adjustments we made were consistent with FDA recommendations for conducting trials during the COVID-19 pandemic, and the focus was on safeguarding patients while keeping the integrity of the studies intact. On top of that, we have maintained steady communication with the partners who manufacture for us, and as of now there is no meaningful effect on our supply of the drug. I'd like to thank the sites conducting our trials for staying with us during this difficult time, and I'm pleased that, up to this point, our studies have experienced only a slight impact. Up to now, we haven't received any reports about substantial interruptions to treatment or follow-up for patients who are already taking part in our trials. More precisely, there have been no missed disease assessments at all, and nothing notable has changed when it comes to monitoring safety. Some specialized studies have taken a hit — that includes thorough pharmacokinetic evaluations along with tumor biopsies performed while patients are on treatment — because clinical sites shifted their attention to getting ready for, and looking after, a possible wave of COVID-19 patients. Signing up new patients for particular studies has likewise been impacted. From where we stand, the impact of COVID-19 on Corvus as a whole has not been meaningful so far. Prior to the arrival of COVID-19, every one of our trials was seeing really strong enrollment, and because of that, our main focus now can be on oversight and preparing for upcoming studies. A good example is CPI-006. Following our presentation of encouraging early data from that study at ASCO last year, enrollment interest climbed; for this program we are moving faster than our own internal targets, having progressed to the third and fourth arms — CPI-006 paired with pembrolizumab, which has now completed enrollment, and the three-drug arm combining ciforadenant and pembrolizumab, both of which are ahead of plan. When it comes to ciforadenant, we have already wrapped up enrollment in a 25-patient trial meant to verify activity within our biomarker-positive group. At a high level, what we're focused on right now is following and monitoring patients — the aim being to gather data, examine results, and put together follow-up studies. One thing worth highlighting: we're going to look at our ciforadenant data in renal cell cancer as we get ready for a meeting with FDA later this year, where we'll talk about our registration strategy and a pivotal trial. So, moving into a progress update on our programs, I'll start with ciforadenant, which is our small molecule A2A receptor inhibitor. There's a very exciting period ahead for that program. We've had a major abstract accepted for an ASCO presentation in late May. That data is going to give everyone an update on ciforadenant paired with atezolizumab in renal cell cancer treatment, plus how the adenosine gene signature functions as a possible predictive biomarker for the patients likeliest to respond to this therapy. Independent work from other groups strengthens how much faith we have in the biomarker signature, since it backs up its potential — among those is an abstract from a leading academic institution that will be shown at ASCO; that research verifies the adenosine signature's prognostic value in renal cell cancer. We intend to meet with the FDA in Q3 to discuss the trial design and our strategy for a randomized pivotal study of ciforadenant in renal cell cancer patients who have already undergone two or more prior lines of therapy, utilizing the adenosine gene signature biomarker. In addition, we plan to explore whether a single-arm trial based on that adenosine signature could be feasible. As you may recall, this signature identifies a group of patients with particularly poor prognosis — what amounts to a distinct subset of renal cell cancer — and we believe that those who test positive for the biomarker will respond better to ciforadenant while doing worse on conventional treatments, which could create an opportunity in an area of unmet need. Now regarding CPI-006, the anti-CD73 antibody that activates B-cells — our excitement about this immunomodulatory antibody remains strong because of the striking impact it's had on immune cells in circulation, mobilizing and redistributing both B-cells and T-cells. We're not aware of any other treatment — whether an antibody or small molecule, targeting CD73 or anything else — that has demonstrated these kinds of properties. As we've shared before, CPI-006 produces powerful effects on B-cells, triggering their activation, their conversion into plasmablasts, and the release of IgM and IgG antibodies. In total, over 75 patients have been enrolled thus far in the CPI-006 trial, which is evaluating the antibody as a monotherapy, alongside ciforadenant, alongside pembrolizumab, and in a triplet regimen combining it with both ciforadenant and pembrolizumab. Later this year, in November, at the SITC meeting, we intend to share an update regarding this work. A promising new possibility involves employing CPI-006 as a treatment to boost antibody responses. In certain cancer patients who received CPI-006, we have observed the generation of anti-tumor antibodies. Finally, regarding CPI-818, our ITK inhibitor, we have determined its safety profile, pharmacokinetics, receptor occupancy, and the optimal dose, as well as preliminary indications of anti-tumor activity. Drawing on patient responses from the initial segment of the phase I-B study, we intend to proceed with the subsequent segment of this trial, focusing at first on cutaneous T-cell lymphoma. Thus far, the study has generated valuable data regarding dosage, selectivity, pharmacokinetics, and target engagement. That gives us a strong foundation going forward, both for lymphoma and for autoimmune conditions. In closing, our pipeline continues to show healthy progress. We've managed this while deploying capital in a highly efficient manner, and we now have three programs in clinical development. Importantly, we may be in a position to start a pivotal study of ciforadenant alongside the adenosine gene signature in renal cell cancer as soon as early 2021. A major step toward that goal will be our presentation of the latest findings from this program at ASCO. We look forward to providing an update at that time. At this point I'll hand the call to the operator so we can take questions and answers. Operator? All right. Mara?

Mara Goldstein

analyst
#4

Is this audible for you at this point?

Mara Goldstein

analyst
#5

Perfect, thanks. My apologies for that. Only two or three items. The initial one concerns the ITK inhibitor. As you consider moving it forward and the clinical development route for this agent, what scenario seems most probable regarding a clinical trial, given that a comparator showing where it lands within the treatment paradigm may not be available? And then I'm wondering, for the triplet regimen involving CD73, cifo, and pembrolizumab — has that finished enrolling completely?

Richard Miller

executive
#6

I missed the tail end of what you said. It is what?

Mara Goldstein

analyst
#7

And in that triplet, is it already at full enrollment?

Richard Miller

executive
#8

Alright.

Mara Goldstein

analyst
#9

Could you give us a sense of where things stand?

Richard Miller

executive
#10

Sure. Enrollment for the triplet study is nearly complete. As I recall, one or two patients remain to be brought in, though all of them have already been located. That study will reach full enrollment — Mehrdad, correct me if I leave anything out — in 1 or 2 weeks.

Mehrdad Mobasher

executive
#11

No, you're accurate.

Richard Miller

executive
#12

Yeah; that's done.

Mara Goldstein

analyst
#13

All right.

Richard Miller

executive
#14

I'm hoping that clears things up. Enrollment for the doublet is now complete. Now, regarding ITK and what our approach to it should be. To start with, the individuals we've signed up for our trial so far are those in whom every approved treatment for these conditions has already stopped working. Whatever signal we observe among the T-cell lymphoma subjects, and likewise the cutaneous T-cell lymphoma subjects, in our trials deserves attention, since nothing else exists to treat them; these people are very ill. Let me expand on that point somewhat. There are, as you're aware, many treatment options available for lymphomas.

Mara Goldstein

analyst
#15

Right.

Richard Miller

executive
#16

With these lymphomas, some therapies aren't curative, but they still produce a modest amount of minimal activity. Actually, the majority of patients who join our trial have already gone through over five prior lines of treatment. These people are really worn down. In our view, whatever activity we observe among the patients we've been treating deserves attention. Of course, the purpose of our phase I study — specifically the portion we've completed, and that point matters — has been to establish dosage safety, target occupancy, immune system effects, and similar things. Along those lines, the trial has come through successfully in, I'd say, every respect. Our work on this target and our drug has taught us a great deal. One key point stands out: as far as we know, no selective inhibitor of ITK has ever existed.

Mara Goldstein

analyst
#17

Right.

Richard Miller

executive
#18

We're figuring out what happens when we block that target in a very targeted way.

Mara Goldstein

analyst
#19

Okay.

Richard Miller

executive
#20

That's where we are on that.

Mara Goldstein

analyst
#21

All right. So to be clear, the dose in question was 450? Did I get that right?

Richard Miller

executive
#22

Our plan is to proceed with 600.

Mara Goldstein

analyst
#23

Oh, you are. Okay.

Richard Miller

executive
#24

600 milligrams of BID.

Mara Goldstein

analyst
#25

All right. Do you have any idea how large that control group might be, taking into account CTCL, the size of that patient group at the outset, and the reality that these individuals will have already gone through so many treatments? Roughly how big a study would you be seeking?

Richard Miller

executive
#26

To start with, we remain in the phase I-B portion of this, so additional patients will be treated. We'll develop a sense of the activity, and after that we will put together the new trials and proceed from that point.

Mara Goldstein

analyst
#27

All right.

Richard Miller

executive
#28

One great aspect of CPI-818 is its strong safety profile up to this point. A number of individuals have received this therapy daily for several months at this stage. It's quite appealing at this point to consider it not just as a monotherapy, but as you're aware, Mara, the majority of our lymphoma treatments involve combinations. We're now starting to consider which types of therapies to pair it with, how we advance it higher within the treatment paradigm, and so on.

Mara Goldstein

analyst
#29

Okay, that's fine, thank you, and I do value that. I'll step away and give someone else a chance to speak.

Tony Butler

analyst
#30

Richard, I have two things to ask too. Let me return to that CPI-006 trial. If I'm mistaken, please set me straight, but on ClinicalTrials there were six cohorts, right? And with the assumption of 378 patients being enrolled, does that get split evenly across all six, meaning cohort 1A through C plus cohort 2A through C? That's my first item. My second item concerns the registration study you're expecting to launch next year in second, third, or fourth-line RCC. I'm interested in what shape you believe it takes. Is it only prior failures, given that, as you're aware, atezolizumab or a PD-1 have been or are increasingly given in the frontline? Would you just combine standard of care with cifo, or would you add atezolizumab alongside? I'm simply wondering how you're thinking about that, both from a control perspective and from a registration perspective. That's independent of whatever happens with the single arm trial. Naturally, every one of those patients will carry adenosine signatures. Many thanks, Richard.

Richard Miller

executive
#31

Okay. Mehrdad, would you like to take on both of those questions, in fact?

Mehrdad Mobasher

executive
#32

Yes. Regarding your second question about the landscape, you're correct. Today, nearly every patient receives immunotherapy as frontline treatment—PD-1 in the frontline setting. Keep in mind, what we demonstrated with the signature is that it pinpoints those patients who will not respond well to immunotherapy. Our approach involves administering ciforadenant to them, and the concept is that it will be used alongside a PD-1 or PD-L1, based on what we also understand about the mode of action and resistance mechanism for those agents, and that is how these patients will be rescued. The study will be powered for signature positive patients. Did that cover the second question?

Richard Miller

executive
#33

So perhaps—

Tony Butler

analyst
#34

Indeed, you did.

Richard Miller

executive
#35

All right, understood.

Tony Butler

analyst
#36

Tony Butler here — Richard, the floor is yours whenever you're ready.

Mehrdad Mobasher

executive
#37

Mehrdad Mobasher takes it from there: go right ahead; I've got this one.

Richard Miller

executive
#38

No, go ahead. I think you did answer it. That's fine.

Richard Miller

executive
#39

Tony, regarding your first question on CPI-006 — let me try to recall the details, since I can't bring up everything on clinicaltrials.gov from memory. Some cohorts were added after the study began. This trial has four cohorts, and there were four cohorts. CPI-006 as a single agent; CPI-006 combined with ciforadenant, the concept being that you're blocking two adenosine nodes along the pathway; the third arm paired CPI-006 with Pembro as a doublet; and the fourth arm gives all three together — CPI-006, cifo, and Pembro. All of those have been enrolled except the triplet, the final cohort, which is nearly fully enrolled, as we said before. We then had dose escalation within each cohort, since safety has to be established for the monotherapy and for the combinations, even though the timing was staggered somewhat. We moved from 1 milligram per kilogram up to 24 milligrams per kilogram, and we determined that 18 milligrams per kilogram given intravenously once every three weeks is the correct dose across the board. That's what we're using in all four cohorts. Inside each cohort, there's room to extend and examine renal cell, lung, and prostate, and I believe there's an other category as well. So there are essentially four buckets for each of the four arms. Many of those have been enrolled, but while running the trial, we've tended to move patients across — and that's one of the great advantages of this trial — we can direct patients toward perhaps a closer look at the combination rather than the monotherapy; we won't fill every bucket of all 4 cohorts because we don't believe that's needed, and we've seen evidence suggesting some of the combinations may matter more.

Tony Butler

analyst
#40

Understood. And if I could pick up on that same point — please tell me if I've got this backwards — my understanding is that the triplet is the one that has shown some of the stronger results we've observed so far, even though the group was small. It makes sense to me that you'd move patients elsewhere, but I'd simply like to verify that this matched what you were seeing too.

Richard Miller

executive
#41

So, regarding the triplet, we still don't have sufficient data on it. Of all the cohorts we've enrolled, the triplet came last, which means its data is the least mature and it currently has the fewest patients. Naturally, that will mature over time. Roughly more than 30 patients are in this trial right now, and they remain on active therapy. This is still in progress. One point Leiv stressed when he introduced things, and one I attempted to stress too, is that our enrollment and our execution have been so strong across the last 1 to 2 years that we've effectively filled the fuel tank. Now we're able to run, treat these patients, and begin examining safety and efficacy data along with biomarker data, and begin reaching some decisions. That's the reason I don't believe this COVID pandemic has affected us much — thankfully, we had already obtained most of what we required from enrollment before it struck. At this point it's about allowing this data to mature; we currently have many patients receiving therapy throughout our trials. So now the task is to let the data mature, analyze it, and, as I mentioned, proceed to the next steps once we determine the answers. Is that clear?

Tony Butler

analyst
#42

Yes, sir, that's right. Thanks a lot, Richard. I'm grateful for that. Mehrdad.

Richard Miller

executive
#43

If you're asking me which among the 4 cohorts looks superior at this point, there's a hunch that the combo is superior, though I wouldn't claim there's evidence for it — no evidence exists for any of that. What is beyond any doubt whatsoever, completely beyond doubt at this stage, is the effect on the immune system; we think in an extremely favorable manner, the effect on B cells, on lymphocyte trafficking, on humoral immunity is deep. It's truly remarkable. That shows up even at a dose of 1 milligram per kilogram. There's novel biology at work here that nobody has ever described previously. It isn't tied to adenosine. I can't exclude that possibility, but we observe these effects in vitro even when adenosine is removed from the picture. This won't be observed. We have other antibodies against CD73 that likewise block adenosine production, binding to different epitopes; that's not the mechanism; this antibody, 006, binds to a different region of the CD73 protein that carries an immunostimulatory effect, which, incidentally, was initially described back in the 1990s. We were aware of that. To our knowledge, we don't believe anyone — we don't believe any small molecule or any other antibody we've heard of or encountered possesses this property.

Tony Butler

analyst
#44

Richard, many thanks. I appreciate you taking the call.

Swayampakula Ramakanth

analyst
#45

Thank you, Richard. How are you doing this afternoon?

Richard Miller

executive
#46

Good.

Swayampakula Ramakanth

analyst
#47

I've got two things I'd like to ask. Because I've been switching back and forth between calls, it's possible you already covered this, but I'll go ahead anyway. Regarding what backs the CPI-006 program, in the phase I-B/II study, some results are anticipated at ASCO; beyond that phase I-B/II study you're referring to, what does the road ahead look like? My other question concerns the 818 phase I/I-B study — when should we expect data there, and how do you see the development pathway unfolding from this point?

Richard Miller

executive
#48

All right. I'll begin with the cifo, and then I may invite Mehrdad to weigh in too. You'll remember that back in January we had a publication in Cancer Discovery, with Lawrence Fong of UCSF as first author. What we reported involved 68 patients whose disease was advanced and refractory, predominantly renal cell cancer that had failed PD-1. In that paper, among patients testing positive for the adenosine signature, the response rate by RECIST criteria came to 17%. Quite a few patients also fell just short of the criteria for PR yet experienced meaningful tumor shrinkage. We further reported a favorable plateau — one that persisted a long time — on the progression-free survival curve; this was tied to the adenosine signature with statistical significance, and among the adenosine signature negative group, nobody responded — zero. Naturally, we were aware of these findings prior to the January publication, and we told ourselves, "Fine. For now this is an observation. Let's go confirm it prospectively." We aimed to enroll roughly 25 patients. My sense is we've got 26 or so enrolled. Those 26 added patients include both adenosine signature positive and negative cases. That's because, once again, confirmation is needed for the positives and equally for the negatives. With the follow-up available on those added patients — and again, some follow-up is brief for those added 25, 26 patients — that will form the basis of our ASCO abstract; it won't come as a surprise. The findings are holding up; we figured they would. They're holding up really well. Also at ASCO, as I noted during my remarks, there's an excellent paper from people at Sloan Kettering — I suppose I'm allowed to name them — covering hundreds of patients, in which they examined the adenosine signature on their own and asked, "How do these patients fare prognostically?" Their findings match ours precisely. When you're adenosine signature positive, your outcome is quite poor. Naturally, those Sloan Kettering patients aren't receiving adenosine antagonists. They're on standard therapy; at this point we feel quite confident about this signature. That positions us for a trial defined by biomarker. I should add that our early work also revealed that roughly 60% of renal cell cancer patients test positive for the adenosine signature. The latest figure I have is around 68%, which lands in that same vicinity, so roughly 60% or perhaps two-thirds of patients test signature positive. That's a meaningful share of the population, and their outcomes are quite poor. Between what we've done, what Sankyo has done, and what we've heard from other companies, I believe there's no doubt we've essentially characterized a new disease, given how badly these patients fare. This is the group in which our drug shows activity. That positions us well for a strong trial, and we now have choices: either enroll everyone and run some type of hierarchical analysis, or narrow our focus to the signature-positive patients. Those decisions will be made over the next few months. Dr. Mobasher has been collaborating with leading renal cell cancer experts. They're making solid progress. A protocol is in place that would lay out a pivotal randomized study. I'll ask him to add a bit more on that. Mehrdad, would you like to speak broadly about what we're planning there?

Mehrdad Mobasher

executive
#49

Right. As you were saying, according to the early data, our strategy is that we've pinpointed this population of poor-risk patients — they genuinely require a new therapy — and from what our data show, we believe these are the people who'd gain from our treatment. A steering committee has been put together. We're focused on generating our pivotal data, which will be powered in signature patients, and in our view that represents a significant route, one that's going to be talked over with the health authority.

Swayampakula Ramakanth

analyst
#50

Richard, thanks. Mehrdad, thanks as well.

Richard Miller

executive
#51

You raised a question too about the timeline for 818. Regarding that timeline, what we're doing is tracking the patients currently enrolled in the study. Additional patients with cutaneous T-cell lymphoma will be enrolled, purely because we believe that disease is a highly suitable fit for this drug. Honestly, one could argue in favor of enrolling additional patients who have the other T-cell lymphomas too, but our aim is to narrow the focus somewhat here. Like others, we've also grown quite intrigued by some of the other immune disease applications, and we're beginning to explore that. In autoimmunity, we suspect this could prove to be a quite compelling disease. Our own work in that field isn't extensive, but we have started collaborating with particular individuals at NIH, for instance. To my mind, the ASH Meeting could be a great venue for providing an update on that, though we'll see how matters develop there.

Swayampakula Ramakanth

analyst
#52

Great. Really appreciate that, Richard. Thanks.

Richard Miller

executive
#53

All right.

Gabriel Fung

analyst
#54

Hey, everyone. Gabriel here, calling in from Mizuho Securities — I'm also on with Mara. Congratulations to the team. It's really exciting to hear that a pivotal program is right around the corner. I just wanted to build on what was said a moment ago regarding the pivotal study. Would you expect that an all-comers arm directly compared against an adenosine signature-selected arm would be necessary for ciforadenant — sorry, I mean for ciforadenant? And how do you see that affecting the market opportunity? I think you already noted that roughly 68% of patients test denosig positive. Assuming this does work, how might it potentially fit into earlier lines of therapy? Thank you.

Richard Miller

executive
#55

Mehrdad, would you like to address that?

Mehrdad Mobasher

executive
#56

Yeah, regarding whether a superior trial design would involve enrolling all patients or only those who are signature positive — everything we've seen so far points to signature positive patients being the group that achieves objective responses. Like Richard said before, those patients end up with a fairly extended progression-free survival period, which is what created a tail on that curve. Operationally speaking, either approach could work, and that's exactly the thing we're working to refine alongside our steering committee as well as the health authorities. I believe that covers the first portion of your question, based on how I've addressed it. Now for the second portion: we see this as an ideal therapy when it comes to the treatment landscape for patients in the second line and the third line, since those are the individuals receiving immuno-oncology therapy. Again, drawing on the mechanism of action, our belief is that these patients won't respond, and instead they'll show a good response to what we're offering. In oncology, the usual instinct is to rescue patients as early as possible. There's a possibility of shifting this treatment into the front line too, combined with the ciforadenant, whatever the backbone turns out to be. That isn't where our focus lies right now. It's something we're exploring down the road.

Richard Miller

executive
#57

Mehrdad, that's a fair observation. Let me build on it a bit: a really appealing aspect of ciforadenant — and we've got data now, more than 350 patients — is that some people have been on this medication for more than a year at this point. I believe a few have been on it daily for over two years.

Mehrdad Mobasher

executive
#58

Three years.

Richard Miller

executive
#59

My mistake — three years. Mehrdad, you seem older than that to me. Regarding this drug — and people have already raised this question — combining it with front-line treatments would be quite straightforward from a safety perspective. Without a doubt, as with numerous drugs, our approach is to seek approval in later lines, then shift it earlier; these days, renal cell cancer is transforming considerably. Clearly, the landscape is shifting at a rapid pace. Patients survive longer. They reach 2nd, 3rd, 4th, 5th lines of therapy. In a way, it's turning into something akin to a chronic lymphoma. That grows, and at this stage you begin considering not the incidence of the disease, but the prevalence. Prevalence will likely rise. We actually anticipated this three or four years back; as far as the market goes, I believe our market for renal cell would be extremely strong. As a small company, that's certainly appealing. Keep in mind the adenosine signatures in other tumors; that's something we've been examining. In fact, a paper was just submitted for publication by Daniel Willingham and Drew Hotson that examined this and demonstrates the distribution of the adenosine signature from TCGA data. It shows up in other tumors. It's incumbent on us to determine which tumors our drug will be applicable to based on using that signature; that requires more work going forward. I think it would be a mistake to restrict this or view it purely as a renal cell cancer play.

Gabriel Fung

analyst
#60

Right.

Richard Miller

executive
#61

Biologically speaking, these are all extremely, extremely alike. Almost identical across the board.

Gabriel Fung

analyst
#62

Okay.

Richard Miller

executive
#63

One item that will come up at our ASCO, and it's included in our abstract — I suppose those abstracts aren't out yet — is that the adenosine signature relates to other factors, plus other cell infiltrates, myeloid cell infiltrates. Independently, others have called this a myeloid signature. We have pinpointed those myeloid cells; that will be shown during our ASCO presentation. Such myeloid cells appear not only in renal cell cancer; they show up in numerous other cancers too. The positive side here, I'd say, is the possible use in tumors beyond renal. Let me step back briefly. It isn't an everyday event to define a new subset of an illness using a biomarker. My team — scientific and clinical — along with our biometrics team, has my deep pride. Defining a new category of a disease is significant, and it builds a career; within academic medicine, that's a move that makes a career. Consider that, consider these other cancers and the way we speak now of squamous versus non-squamous. Once, we didn't separate those. Hodgkin's lymphoma and non-Hodgkin lymphoma. Again, at one time we had no idea what set them apart. Diffuse large B-cell lymphoma from follicular lymphoma. Again, genuine breakthroughs like this were needed to determine, to tell apart these diseases, which truly steered treatment, which opened greater chances to create drugs, since you then understood what distinguished these diseases and what to look for. If not, you're treating a group of different conditions with differing biological, morphologic, and clinical characteristics; that is a huge, huge matter; now we must attempt to make drugs that cure it. That is our aim.

Gabriel Fung

analyst
#64

Great. That actually brings up a quick follow-up question, since I'm aware you also have programs in non-small cell lung cancer and prostate. What's the timeline for hearing about those?

Richard Miller

executive
#65

So for prostate, we presented data only a couple of months back. We're seeing activity there. I believe others are reporting some activity in prostate as well. Patients are enrolled in that trial, and we're tracking them. The long-term outcome for those patients is something we're interested in. More work in that area will probably happen. What exactly that looks like, I can't say at this moment; prostate is a competitive space we're exploring. There are lots of effective treatments; simply being active isn't sufficient. Some advantage is required. Regarding lung cancer, we're tracking patients in the MORPHEUS program with Genentech. There may be some plans to present that data at ESMO, I believe. That's uncertain, though. The patient number is small. What to expect from that, I genuinely don't know.

Gabriel Fung

analyst
#66

Got it. All right. Thank you.

Richard Miller

executive
#67

And-

Richard Miller

executive
#68

Alright. Appreciate it, operator. To start, I want to say thanks a lot for being with us today; these are not normal circumstances. We're glad each of you was able to take part in this call. It was a pleasure talking with you, and we're eager to share further updates at some point before long at ASCO and past that as well. Many thanks.

Operator

operator
#69

Thanks. That wraps up today's conference. We appreciate your taking part.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.